.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as total survival, triggering FDA commendation as well as a brand new procedure possibility for patients.